Edwards Lifesciences announced Nov. 6 that it had received expanded CE mark approval in Europe for the use of its SAPIEN 3 transcatheter heart valve, a tool designed to facilitate TAVI in patients who don’t want to undergo open-heart surgery.
An increase in public reporting of aortic valve surgery outcomes has been tied to a decrease in AVR access for patients with infective endocarditis—the unintended consequence of a push for greater transparency in healthcare.
Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.
An economic analysis of COAPT data suggests edge-to-edge TMVR with the MitraClip device is a more affordable long-term treatment option than guideline-directed medical therapy alone for patients with severe secondary MR—but the steep cost of an index TMVR procedure might eclipse that benefit.
The incidence of aborted procedures during transcatheter aortic valve replacement is falling, according to work published in JACC: Cardiovascular Interventions, but centers with low institutional TAVR volume still struggle to keep up with bigger hospitals’ success.
The need for surgical bailout in heart patients undergoing TAVR is low, according to research published in JACC: Cardiovascular Interventions, but when it is performed outcomes are poor, reaching 50% mortality at 30 days.